AzTrials
AzTrials

DehydrationPhase 2DRINKNCT06788795

Effectiveness of a Wearable Hydration Device

A Phase 2 study testing Device with Phone App and Device without Phone App in people with Dehydration and Syncope and Collapse, run by MetroHealth Medical Center.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

Dehydration among older adults a costs billions of dollars in US healthcare every year because no robust solution exists to detect changes in hydration and prevent negative outcomes. In this project, TritonX Technologies Inc. Read more about this study

Who is it for?
Ages 55 years and older
Conditions the study is for
Dehydration, Syncope and Collapse
What is being tested?
Device with Phone App and Device without Phone App
Type of treatment
Medical device
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
150 participants
Where
No sites listed yet
Study dates
1 Apr 2025to 31 Dec 2026
Phase
Phase 2
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 55 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • adult patients aged 55 and over
  • rresenting to the emergency department
  • clinical suspicion of dehydration
  • treatment of dehydration/syncope with fluid resuscitation
  • English speaking

Who cannot join

  • Refusal or inability to give informed consent,
  • severe clinical symptom requiring escalation of care beyond fluid resuscitation (ex. vasopressors, invasive blood pressure monitoring)
  • presumed/confirmed diagnosis of syncope secondary to a non-dehydration cause (ex. arrhythmia, stroke, pulmonary embolism, sepsis, valvular heart disease)
  • inability to lay flat for the test
  • body weight greater than 350 lbs
  • inability to fit measurement devices around the participant wrist
Show all 11Show fewer
  • abnormal bodily fluid retention (lymphedema, ascites, pleural effusions, peripheral edema)
  • neuromotor disorders
  • current congestive heart failure exacerbation or heart attack/myocardial infarction
  • any implantable electronic devices
  • skin on limbs in poor condition (excessively, dry or rough or abrasions or wounds that would preclude application of electrode adhesive)

Trial locations and contacts

No sites are listed yet. Contact the study team or a site near you to ask about taking part.

Joseph S Piktel, MD contact

216-778-2864

jpiktel@metrohealth.org

Julie Nichols, RN contact

216-957-6488

jnichols@metrohealth.org

About this study

Official title: Clinical Effectiveness of a Wearable Hydration Device

Dehydration among older adults a costs billions of dollars in US healthcare every year because no robust solution exists to detect changes in hydration and prevent negative outcomes. In this project, TritonX Technologies Inc. and academic research partners plan to test whether a newly created wearable sensor that measures hydration in real time can promote hydration and prevent the dehydration illnesses.

The investigators will conduct a randomized controlled trial to examine the effectiveness of continuous home monitoring of fluid levels in a cohort of vulnerable older adult patients seen in the emergency care setting.

Read more

The goal of this randomized control trial is to examine the effectiveness of continuous home monitoring of fluid levels in older patients presenting to the emergency department for dehydration. The main questions it aims to answer:

  1. Can a wearable device accurately determine the severity of dehydration at home and
  2. can a wearable device and continuous feedback from the device change behavior in the outpatient setting that can lead to improved outcomes in the treatment of dehydration in the elderly?

Investigators will compare device readings, hydration diaries, vital signs, blood samples, return visits to the emergency department, and to see if feedback from the device decreases signs and symptoms of dehydration and changes home management of dehydration.

Participants will be asked to:

  • wear the device and monitor hydration status
  • record the amount of home hydration
  • return in 7-10 days for reassessment of dehydration

The successful outcome of this study will include evidence for the effectiveness of the home, wearable hydration monitoring device, data necessary for the FDA 510(k) and related regulatory processes and substantial enhancements to both our knowledge of older adult needs and device functionality.

Read the detailed description

Dehydration is common and costly: Dehydration is characterized by a decline in total body water. Dehydration is considered to be hypotonic when accompanying salt loss occurs and hypertonic if caused solely by water loss. Hypertonic dehydration is associated with mortality and severe short- term and long-term neurological sequelae. Annual costs of hospitalization primarily due to dehydration have been estimated at $1.36 billion. Approximately 17% of older adults hospitalized for dehydration die within 30 days, as often multiple organ systems are detrimentally affected by dehydration. Dehydration is not only widespread among older adults, but also an independent predictor of mortality. A number of studies have reported mortality rates associated with hypernatremia (a high sodium level that often accompanies dehydration) at greater than 40% and are commonly related to the underlying disease processes.

The cost of dehydration is twofold - one is the direct cost of dehydration on the patient and US healthcare; and second is its indirect effects as a comorbidity of another disease. For example, delirium is commonly caused by dehydration among older adults. In individuals with underlying dementia mild dehydration causes further cognitive impairment and possibly hallucinations, delusions, anxiety, and agitated behavior. Dehydration can also trigger other medical complications, such as infections, constipation, kidney stone formation, worsening aortic stenosis, valvular disease, adverse drug reactions, urinary tract infection, pneumonia, pressure ulcers, metabolic imbalance, uncontrolled diabetes, gastroenteritis, and some forms of cancer. According to an AHRQ study of the Nationwide Inpatient Sample (NIS) representing all patients in acute care hospitals, dehydration was diagnosed more commonly as a comorbidity than as a principal diagnosis. Dehydration was the second most common comorbidity, occurring in 14% of all hospitalizations. Thus, dehydration may contribute to the increase of medical costs in an indirect way. It may be a marker of the severity of the underlying disease, or it may add its own complications to those of the underlying disorder. Using direct costs alone, the potential annual U.S. savings from avoidable hospitalizations in these patients could have been as much as $1.14 billion. Dehydration is difficult to detect in real-time with traditional technologies: Primary reasons for the high prevalence of chronic dehydration among older adults are: (1) Older persons have metabolic and olfactory changes (2) medication regimens and disease consequences that can alter to their own fluid intake or the body's ability to maintain fluid levels (3) In older patients, access and maintenance of proper hydration is more difficult; for example, behavioral changes can include not wanting to drink to avoid incontinence in public and (4) traditional technologies do not present a simple, straightforward approach to measuring dehydration. Traditional measurement techniques are either obsolete, time consuming, inaccurate or not feasible. In our market survey, the investigators found that in current care settings care personnel check dehydration primarily through the use of visual signals or inferentially via blood-based indicators (e.g. sodium levels, creatinine). Skin elasticity checks, by pinching on hand or on the forehead, or checking the tongue (dry mouth), are still common. Not only are these methods are obsolete and inaccurate, care personnel are often skeptical of the results. Far too often, care personnel do not detect a dehydration in an older person until they are seriously ill and in need of emergency medical care.

Current Laboratory methods to detect dehydration: There are a few existing methods that can detect dehydration i.e. measure Total Body Water (TBW), intracellular water (ICW), and extracellular water (ECW). The tests involving urine, blood, or isotopic dilution are generally invasive, impractical or have not been adopted in either acute care or home settings. Furthermore, these tests can be difficult or impossible to repeat at regular intervals, precluding the opportunity to be used proactively and prevent dehydration. Total body composition machines on the market, which are based on bioimpedance measurement techniques have shown to be accurate and to deliver acceptable results in real time. However, a critical limitation of these devices is their size and thus ease of use in everyday setting. Other important barriers to using these devices for routine detection of dehydration include the electrode placement requirement (wrist to ankle or both hands and feet), equipment cost (>$10,000 per device) and no way of measuring the changes in the body fluids over time. To date, these devices are used almost exclusively in research or subspecialty care settings. Thus, even though these methods show promise of detecting dehydration in general, a simpler efficacious solution for measuring dehydration among community living older adults is highly desirable.

The D.R.INK device can detect falling hydration levels and alert individuals and care personnel to respond appropriately. Our proposed project will provide evidence for how our solution is transformative for inpatient, institutional care and community care settings alike by 1) making it user friendly to the population 2) ensuring its accuracy based on previously identified clinical and laboratory parameters 3) testing accuracy and effectiveness in a randomized observational setting and 4) determining how DRINK changes behavior and improve clinical outcomes. Thus the investigators expect that our real-time and accurate hydration monitoring device, has the potential to greatly reduce costly acute care among older adults. The band is expected to not only improve the overall quality of life older adults but also reduce the morbidity and mortality, by enabling the proactive detection of an avoidable condition: dehydration.

A key advantage of the DRINK technology over other methods is that the device can detect changes in fluid levels by collecting longitudinal data within person at regular intervals outside of the clinical settings. In addition to the immediate benefits in our proposed work the investigators expect a wide range of future applications and the ability to uncover tremendous health insights.

This project aims to:

  1. Examine the effectiveness of continuous home monitoring of fluid levels. Hypothesis 1: A wearable hydration device improves recovery after acute care for dehydration Hypothesis 2: A wearable hydration device reduces acute negative health events among a vulnerable population of older adults at risk for dehydration.
  2. Combine clinical expertise and results from outcomes measurement to define measurement indicators, propose clinically actionable thresholds, safety guidelines and improved visualizations for patients and care teams.
Being tested
Device with Phone App, Device without Phone App
Keywords
dehydration, total body water, bioimpedence, emergency department
Medical subject headings
Dehydration, Syncope, Emergencies

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Device with Phone AppDevice

    This is the intervention where the patients will be given both the wearable dehydration device as well as the phone app

  • Device without Phone AppDevice

    This is the intervention where the patients will receive the device alone

Study groups in NCT06788795
Study groupRoleWhat they receive
Device with Interactive Phone AppActive comparatorIn this arm, patients will receive the wearable dehydration device and receive the phone app, which will include prompts to check their dehydration status and to drink more fluids if necessary
Receives: Device: Device with Phone App
Device without Interactive Phone APpSham comparatorIn this arm, patients will receive the wearable dehydration device without the phone app
Receives: Device: Device without Phone App

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Average daily fluid intake in mL

    The average daily fluid intake over 10 days as determined by a standardized Drink Diary

    Measured: 10 days

Secondary outcomes (10)
  1. Level of total body water after 10 days

    Total body water after 10 days will be determined by the wearable dehydration device

    Measured: 10 days

  2. Midpoint Clinical symptoms of dehydration

    Midpoint telehealth visit reports of syncope, dizziness, feeling of confusion, increased thirst, reported decreased urinary output, feeling fatigued

    Measured: 5 days

  3. End of Study Report of Dehydration

    Any reported syncope, dizziness, feeling of confusion, increased thirst, reported decreased urinary output, feeling fatigued.

    Measured: 10 days

  4. End of Study Visit Heart Rate (beats per minute)

    HR >100 would be considered abnormal

    Measured: 10 days

  5. End of Study Visit Blood Pressure

    Systolic and diastolic blood pressure (mmHg)

    Measured: 10 days

  6. End of Study Visit Orthostatic Vital Signs

    HR and BP upon standing and sitting. HR rate of change greater than 30 bpm or symptoms of dizziness would be considered positive

    Measured: 10 days

  7. End of Study Visit Serum Osmolality

    measured in mOsm/kg

    Measured: 10 days

  8. End of Study Visit Serum Sodium

    measured in mEq/L

    Measured: 10 days

  9. End of Study Visit Serum Creatinine

    measured in mg/dL

    Measured: 10 days

  10. End of Study Visit Glomerular Filtration Rate

    estimated GFR in milliliters per minute per body surface area

    Measured: 10 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 Jan 2025
  2. Study start1 Apr 2025 (estimated)
  3. Primary completion1 Jul 2026 (estimated)
  4. Study completion31 Dec 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Care provider, Investigator
Enrolment
150 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06788795
Sponsor's protocol ID
STUDY00000196
Other IDs
R42AG080886
Acronym
DRINK
Status last verified
Feb 2025
First submitted
11 Dec 2024
Last updated
13 Mar 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: Summary data will be available but we may not share individual data due to concern for patient privacy

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Device with Phone App and Device without Phone App in people with Dehydration and Syncope and Collapse, run by MetroHealth Medical Center.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 13 Mar 2025. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Joseph S Piktel, MD (216-778-2864, jpiktel@metrohealth.org), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Average daily fluid intake in mL (time frame: 10 days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Mar 2025.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in